Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | GCK | P35557 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107670 | 0.88 | KMT2A (0.56) | KMT2AGCK | |
| SCHEMBL1107687 | 0.86 | SMN1; SMN2 (0.49) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL12742943 | 0.85 | GCK (0.48) | ALDH1A1GCK | |
| SCHEMBL12742894 | 0.83 | GCK (0.61) | GCK | |
| SCHEMBL1263418 | 0.82 | GCK (0.60) | NPC1RAB9AKMT2AGCK | |
| SCHEMBL12742920 | 0.81 | GCK (0.54) | ALDH1A1GCK | |
| SCHEMBL12594260 | 0.81 | GCK (0.47) | MTNR1AMTNR1BMEN1KMT2AGCK | |
| SCHEMBL1140707 | 0.80 | GCK (0.61) | MAOBGCK | |
| SCHEMBL12742905 | 0.80 | GCK (0.61) | MAOBGCK | |
| SCHEMBL10989419 | 0.80 | KMT2A (0.53) | MAOBALDH1A1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | MAOB 2842/4885MTNR1A 2005/4885MTNR1B 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.